Fluticasone vilanterol
Pro Research Analysisby 
Searched over 200M research papers for "fluticasone vilanterol"
Fluticasone Vilanterol: Efficacy and Safety in COPD and Asthma
Introduction to Fluticasone Vilanterol Combination Therapy
Fluticasone furoate and vilanterol is a combination therapy used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Fluticasone furoate is an inhaled corticosteroid (ICS), while vilanterol is a long-acting β2-agonist (LABA). This combination aims to improve lung function, reduce exacerbations, and enhance overall respiratory health.
Efficacy in COPD Management
Impact on Exacerbations and Lung Function
Several studies have demonstrated the efficacy of fluticasone furoate and vilanterol in reducing COPD exacerbations. In two replicate trials, the combination therapy significantly reduced the rate of moderate and severe exacerbations compared to vilanterol alone . A pooled analysis confirmed these findings, showing a consistent reduction in exacerbation rates across different dosages of fluticasone furoate .
Additionally, the combination therapy has been shown to improve lung function. A study comparing different strengths of fluticasone furoate and vilanterol found significant improvements in forced expiratory volume in 1 second (FEV1) compared to placebo and individual components . Another trial confirmed that the combination therapy provided rapid and sustained bronchodilation over 24 weeks .
Cardiovascular and Mortality Outcomes
The SUMMIT trial assessed the impact of fluticasone furoate and vilanterol on survival and cardiovascular outcomes in COPD patients with heightened cardiovascular risk. The study found that the combination therapy did not significantly affect all-cause mortality or cardiovascular events compared to placebo . However, it did reduce the rate of FEV1 decline and exacerbations, indicating potential benefits in respiratory outcomes .
Efficacy in Asthma Management
Improvement in Pulmonary Function
In asthma patients, fluticasone furoate and vilanterol have shown significant improvements in pulmonary function. A meta-analysis of randomized clinical trials reported increases in trough FEV1 and peak expiratory flow rates (PEF) compared to fluticasone furoate monotherapy and fluticasone propionate . The combination therapy also reduced the rate of severe asthma exacerbations, highlighting its efficacy in asthma management .
Long-Term Safety and Tolerability
A 52-week study evaluated the safety and tolerability of fluticasone furoate and vilanterol in asthma patients. The combination therapy was well tolerated, with a safety profile comparable to fluticasone propionate . The study reported no significant clinical concerns, although there was a higher incidence of oral candidiasis with the combination therapy .
Biomarker-Driven Treatment
Role of Blood Eosinophil Counts
Blood eosinophil count has emerged as a promising biomarker for predicting the response to inhaled corticosteroids in COPD patients. A secondary analysis of two trials found that patients with higher eosinophil counts experienced greater reductions in exacerbation rates with fluticasone furoate and vilanterol compared to vilanterol alone . This suggests that blood eosinophil count could be used to stratify patients for more personalized treatment strategies .
Conclusion
Fluticasone furoate and vilanterol combination therapy has demonstrated significant benefits in managing COPD and asthma. It effectively reduces exacerbations, improves lung function, and is generally well tolerated. While it does not significantly impact cardiovascular outcomes or mortality in COPD patients with heightened cardiovascular risk, it offers substantial respiratory benefits. The use of blood eosinophil counts as a biomarker may further enhance the efficacy of this combination therapy by enabling more personalized treatment approaches.
Sources and full results
Most relevant research papers on this topic
Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: A systematic review with meta-analysis.
Fluticasone furoate-vilanterol combination improves trough FEV1 and reduces severe asthma exacerbations, but differences may not be clinically significant.
DOI